PSNL

Personalis, Inc. experienced several stock events in the past six months. The stock saw a 7.0% gain on October 30, 2025, and secured Medicare coverage for breast cancer surveillance in November 2025 and for lung cancer surveillance in February 2026. The company reported Q4 2025 revenue of $17.3 million, falling slightly short of estimates, and a net loss of -$23.8 million. The stock price decreased by 24.9% from the start of 2026 to May 9, 2026. Dr. Richard Chen was appointed as President on March 16, 2026, to accelerate MRD adoption. In April 2026, Personalis highlighted the clinical impact of its ctDNA monitoring at the AACR Annual Meeting. The company reported Q1 2026 revenue of $15.5 million, a 25% decrease year-over-year, and a net loss of $30.0 million. Clinical test revenue significantly increased, and the company reaffirmed its full-year 2026 outlook. Following the Q1 earnings announcement, Personalis shares saw a minor increase in aftermarket trading.